AFT trading update

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com








1 November 2024

AFT trading update

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today advises that it expects to
announce an operating loss of just under $2 million for the six months to 30
September 2024 when it releases its interim results on Thursday 21 November
2024.
This is primarily due to both International and Asia sales being lower than last
year’s first half, reflecting one-off factors that have affected performance.
Sales to International markets dropped due to a reduction in orders from
several of our largest customers who have been re-sizing stock levels and AFT
notes that this has not affected in-market sales. In Asia, a doctors strike in South
Korea, which has now been resolved, significantly impacting Maxigesic IV
sales.
First half earnings have also been affected by both lower licensing income
and further expensed investment to build AFT’s presence in new territories
including North America, the United Kingdom, Europe, South Africa, Asia, and
AFT’s E-commerce digital channels, where the Company sees strong latent
demand for its broader portfolio of medicines in addition to Maxigesic.
Offsetting this in part, sales and operating profits in Australia and New Zealand
achieved double digit growth in the first half despite subdued economic
conditions.
The Company anticipates a recovery in sales momentum in the traditionally
stronger second half of the financial year. The company remains well
capitalized with net debt at the end of September 2024 of $19.4 million, up
from $16.2 million as at the end of March, but down from $30.6 million at the
same time a year ago.
Whilst the expected first half loss will likely have an impact on the Company’s
full year guidance, there are also a number of initiatives planned and contract
negotiations underway which the Company is assessing in its review of its full
year forecast. The Company expects to be in a position to update the market

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

on its full year guidance when it releases its interim FY25 results on Thursday 21
November 2024.


For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing New Zealand based multinational pharmaceutical company that
develops, markets, and distributes a broad portfolio of pharmaceutical products
across a wide range of therapeutic categories which are distributed across all major
pharmaceutical distribution channels: over the counter (OTC), prescription and
hospital. Our product portfolio comprises both proprietary and in-licensed products,
and includes patented, branded, and generic drugs
1
. Our business model is to
develop and in-license products for in our markets of Australia, New Zealand,
Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-
license our products to local licensees and distributors to over 125 countries around
the world. For more information about the company, visit our website
www.aftpharm.com.